Senti Biosciences Holdings
SNTI
39 hedge funds and large institutions have $209M invested in Senti Biosciences Holdings in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 10 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
1% more capital invested
Capital invested by funds: $207M → $209M (+$1.09M)
0.05% more ownership
Funds ownership: 8.8% → 8.85% (+0.05%)
11% less funds holding
Funds holding: 44 → 39 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.37M |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$2.34M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.36M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$923K |
| 5 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$206K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.79M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.15M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$923K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$867K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$493K |
SNTI Hedge Fund Activity: Q3 2021 in Review
39 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Senti Biosciences Holdings (SNTI) for Q3 2021, worth a combined $209M — up 0.52% from $207M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SNTI and 5 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was ARK Investment Management, adding an estimated $2.37M. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.79M sold.
- 39 institutional investors held Senti Biosciences Holdings (SNTI) as of Q3 2021, down from 44 in Q2 2021.
- Funds reported $209M of Senti Biosciences Holdings stock for Q3 2021, up 0.52% quarter-over-quarter.
- 5 funds opened new Senti Biosciences Holdings positions in Q3 2021 and 10 closed out, a net change of -5 holders.
- The largest Senti Biosciences Holdings buyer in Q3 2021 was ARK Investment Management, an estimated $2.37M added.
- The largest Senti Biosciences Holdings seller in Q3 2021 was Citadel Advisors, an estimated $1.79M sold.
Based on aggregated 13F filings for Q3 2021.